# Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

> **NCT07447050** · PHASE2 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer
- Sarcoma
- Gastric (Stomach) Cancer
- Lung Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Ovarian Cancer
- Liver Cancer
- Genitourinary Cancer
- Gynecologic Cancer

## Interventions

- **DRUG:** Riluzole
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07447050
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07447050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07447050, "Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07447050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*